PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31092810-8 2019 Doxorubicin-treated HeLa cells were stained with Vimentin antibody and sorted by flow cytometry. Doxorubicin 0-11 vimentin Homo sapiens 49-57 1382837-0 1992 Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Doxorubicin 69-79 vimentin Homo sapiens 46-54 1382837-7 1992 Adriamycin-resistant MCF-7 cells express vimentin, have diminished keratin 19 expression, have lost cell adhesion molecule uvomorulin expression, and have reduced formation of desmosomes and tight junctions as determined by reduced immunodetection of their components desmoplakins I and II and zonula occludens (ZO)-1. Doxorubicin 0-10 vimentin Homo sapiens 41-49 1384135-14 1992 This study demonstrates that CR and long disease-free survival are obtainable with the VIM regimen in a small number of patients failing a high-dose doxorubicin-containing first-line treatment. Doxorubicin 149-160 vimentin Homo sapiens 87-90 32106373-5 2020 In the study, the results showed that miR-451a exhibited a significant role in suppressing the drug resistance in lung cancer cells when treated with doxorubicin (DOX) through alleviating epithelialmesenchymal transition (EMT), as evidenced by the markedly reduced expression of N-cadherin and Vimentin, while the enhanced expression of E-cadherin. Doxorubicin 150-161 vimentin Homo sapiens 294-302 32106373-5 2020 In the study, the results showed that miR-451a exhibited a significant role in suppressing the drug resistance in lung cancer cells when treated with doxorubicin (DOX) through alleviating epithelialmesenchymal transition (EMT), as evidenced by the markedly reduced expression of N-cadherin and Vimentin, while the enhanced expression of E-cadherin. Doxorubicin 163-166 vimentin Homo sapiens 294-302 7880731-0 1995 Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. Doxorubicin 129-140 vimentin Homo sapiens 10-18 7880731-9 1995 Our results show for the first time that cells resistant to doxorubicin express vimentin independently of the mdr glycoprotein. Doxorubicin 60-71 vimentin Homo sapiens 80-88 34273686-9 2021 The anti-HCC mechanisms revealed that CAP/GA-sHA-DOX NPs could down-regulate the expression level of Vimentin and P-gp, reverse epithelial-mesenchymal transition (EMT) of tumor cells. Doxorubicin 49-52 vimentin Homo sapiens 101-109 28476800-11 2017 However, levels of proliferating cell nuclear antigen (PCNA) and vimentin (VIM) marginally decreased in Dox-treated clones. Doxorubicin 104-107 vimentin Homo sapiens 65-73 29581735-6 2018 It was observed that doxorubicin resistance in colon cancer also induced epithelial to mesenchymal transition, a decrease in expression of epithelial marker E-cadherin and an increase in the expression of mesenchymal markers, including N-cadherin and vimentin. Doxorubicin 21-32 vimentin Homo sapiens 251-259 28627650-5 2017 When treated with doxorubicin, MCF-7 cells displayed characteristics of EMT, such as, mesenchymal markers (vimentin and fibronectin) and EMT-related transcription factors (Slug and Snail-1) in their RNA expression. Doxorubicin 18-29 vimentin Homo sapiens 107-115 30615851-3 2019 HCC/Dox cells exhibited mesenchymal characteristics, which was evidenced by the up regulation of fibronectin, vimentin while down regulation of E-Cadherin. Doxorubicin 4-7 vimentin Homo sapiens 110-118 28972876-4 2017 Here we established a doxorubicin-resistant breast cancer cell line MCF-7/Adr, and found these cells exhibited an EMT phenotype featured by a fibroblast-like morphology, increased the capacity of migration and invasion, and underwent the changes of molecular markers of EMT including E-cadherin, N-cadherin, and vimentin. Doxorubicin 22-33 vimentin Homo sapiens 312-320 28476800-11 2017 However, levels of proliferating cell nuclear antigen (PCNA) and vimentin (VIM) marginally decreased in Dox-treated clones. Doxorubicin 104-107 vimentin Homo sapiens 75-78 27932314-0 2017 TIS21/BTG2 inhibits doxorubicin-induced stress fiber-vimentin networks via Nox4-ROS-ABI2-DRF-linked signal cascade. Doxorubicin 20-31 vimentin Homo sapiens 53-61 28260043-8 2017 The results showed that HepG2/DOX cells acquired EMT characteristics, with a decreased expression level of E-cadherin and an enhanced expression level of vimentin, and possessed high migratory abilities and invasiveness. Doxorubicin 30-33 vimentin Homo sapiens 154-162 27350211-7 2016 ChNP/siRNA/DOX/CMD was more effective to induce tumour cell death and also could significantly reduce the expressions of HMGA2, vimentin as well as MMP-9 and increase E-cadherin expression. Doxorubicin 11-14 vimentin Homo sapiens 128-136 27755958-7 2016 Then the effects of HMGA2 siRNA and DOX co delivery was assessed in A549 viability and target genes (HMGA2, Ecadherin, vimentin and MMP9) by MTT and real time PCR, respectively. Doxorubicin 36-39 vimentin Homo sapiens 119-127 28335269-4 2016 The Gal-DOX/siRNA-L was created via electrostatic interaction of galactose linked-cationic liposomal doxorubicin (Gal-DOX-L) on vimentin siRNA. Doxorubicin 101-112 vimentin Homo sapiens 128-136 28335269-5 2016 Previous studies have shown that Gal-DOX/siRNA-L inhibited tumor growth by combined effect of DOX and vimentin siRNA than single delivery of either DOX or vimentin siRNA. Doxorubicin 37-40 vimentin Homo sapiens 102-110 27126361-7 2016 Moreover, suppressing ARK5 by siRNA restored E-cadherin and vimentin expression induced by doxorubicin treatment or hypoxia culture. Doxorubicin 91-102 vimentin Homo sapiens 60-68 26690867-7 2015 We also demonstrated reduction of Vimentin with DOX-HA-SPION which is significantly less than both control and DOX. Doxorubicin 48-51 vimentin Homo sapiens 34-42 27398136-6 2016 Treatment of cells with doxorubicin or hypoxia was shown to trigger EMT as evidenced by decreased E-cadherin and increased Vimentin. Doxorubicin 24-35 vimentin Homo sapiens 123-131 26690867-7 2015 We also demonstrated reduction of Vimentin with DOX-HA-SPION which is significantly less than both control and DOX. Doxorubicin 111-114 vimentin Homo sapiens 34-42 24612689-0 2014 Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells. Doxorubicin 71-82 vimentin Homo sapiens 0-8 24612689-11 2014 The main purpose of this study was to investigate changes in invasive and migration characteristics of MCF-7/Dox cell line, after transient silencing of vimentin gene by specific siRNA. Doxorubicin 109-112 vimentin Homo sapiens 153-161 23128467-5 2013 Confocal microscopic data revealed that doxorubicin induces reorganization of cytoskeletal proteins including actin, tubulin and vimentin. Doxorubicin 40-51 vimentin Homo sapiens 141-149 24405590-9 2014 Additionally, compared with the 253J cells, 253J/DOX cells presented the upregulation of E-cadherin, the downregulation of vimentin and the inhibition of migration ability. Doxorubicin 49-52 vimentin Homo sapiens 123-131 19898866-5 2010 METHODS: We analyzed selected markers of senescence and cell death, including possible alterations in vimentin and G-actin cytoskeleton in A549 cells after treatment with doxorubicin. Doxorubicin 171-182 vimentin Homo sapiens 102-110 11550207-4 2001 Treatment of cells with DOX downregulated PSA, E-cadherin, and keratin, and upregulated expression of vimentin and vascular endothelial growth factor (VEGF) mRNA. Doxorubicin 24-27 vimentin Homo sapiens 102-110 14555241-5 2003 Etoposide- and doxorubicin-treated cells showed similar changes in the distribution of F-actin, vimentin and tubulin. Doxorubicin 15-26 vimentin Homo sapiens 96-104 11712680-0 2001 Estimation of changes in vimentin filaments induced by etoposide and doxorubicin in human leukemia cell line K-562 by using immunofluorescence microscopy. Doxorubicin 69-80 vimentin Homo sapiens 25-33 11712680-1 2001 This study was undertaken to examine the influence of etoposide and doxorubicin on the distribution of vimentin in cells of human leukemia cell line K-562 by using immunofluorescence microscopy. Doxorubicin 68-79 vimentin Homo sapiens 103-111 11712680-8 2001 Immunofluorescence studies on K-562 cells treated with doxorubicin showed that cells incubated with 5 microM/l doxorubicin have much diffuse staining pattern of vimentin with delicate reticular structure and with intense staining near one pool of the cells. Doxorubicin 55-66 vimentin Homo sapiens 161-169 11712680-8 2001 Immunofluorescence studies on K-562 cells treated with doxorubicin showed that cells incubated with 5 microM/l doxorubicin have much diffuse staining pattern of vimentin with delicate reticular structure and with intense staining near one pool of the cells. Doxorubicin 111-122 vimentin Homo sapiens 161-169